MOLN

MKT CAP:$167M

Molecular Partners AG

Market Cap

$167M

Healthcare·Biotechnology·🇨🇭 Switzerland·NASDAQ

Healthcare·Biotechnology·🇨🇭·NASDAQ

Stock Price

$4.40+$0.18 (+4.27%)

Apr 23, 2026

Company Details

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, wh...

CEO

Patrick Amstutz

IPO Date

Jun 16, 2021

Website

www.molecularpartners.com

Key Metrics TTM

Revenue

$0

-100.0% YoY

Net Income

-$78M

EPS (Diluted)

-$2.10

Free Cash Flow

-$66M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

FY 2025

Mar 12, 2026

$0-100.0%EPS -$2.10

Q4 2025

Mar 12, 2026

$0EPS -$0.42

Q3 2025

Oct 30, 2025

$0-100.0%EPS -$0.41

Q2 2025

Aug 25, 2025

$0-100.0%EPS -$0.70

Q1 2025

Mar 31, 2025

$0-100.0%EPS -$0.57

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 21	$1M	-$20M	-$24M
Q2 21	$4M	-$16M	-$21M
Q3 21	$4M	-$10M	-$16M
Q4 21	$2M	-$14M	-$20M
Q1 22	$220M	$201M	$194M
Q2 23	$528.2K	-$14M	-$20M
Q3 23	$3M	-$12M	-$17M
Q4 23	$1M	-$14M	-$21M
Q1 24	$3M	-$14M	-$20M
Q2 24	$2M	-$15M	-$20M
Q3 24	$866.7K	-$13M	-$19M
Q4 24	$0	-$12M	-$19M
Q1 25	$0	-$15M	-$21M
Q2 25	$0	-$14M	-$22M
Q3 25	$0	-$11M	-$15M
Q4 25	$0	-$648.0K	-$16M

Valuation

Quarter	P/S	P/E
Q1 21	20.6x	—
Q2 21	22.4x	—
Q3 21	14.4x	—
Q4 21	14.1x	—
Q1 22	0.7x	1.2x
Q2 23	0.7x	1.2x
Q3 23	0.7x	1.2x
Q4 23	0.7x	1.2x
Q1 24	19.5x	—
Q2 24	16.7x	—
Q3 24	21.8x	—
Q4 24	26.4x	—
Q1 25	58.7x	—
Q2 25	192.5x	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 21	-$38M	-$38M
Q2 21	-$29M	-$29M
Q3 21	-$24M	-$25M
Q4 21	-$25M	-$25M
Q1 22	$208M	$208M
Q2 23	-$17M	-$17M
Q3 23	-$17M	-$17M
Q4 23	-$20M	-$19M
Q1 24	-$22M	-$20M
Q2 24	-$20M	-$19M
Q3 24	-$17M	-$17M
Q4 24	-$17M	-$17M
Q1 25	-$22M	-$22M
Q2 25	-$17M	-$17M
Q3 25	-$13M	-$13M
Q4 25	-$14M	-$14M

Capital Expenditures

Quarter	CapEx
Q1 21	$203.6K
Q2 21	$432.7K
Q3 21	$532.0K
Q4 21	$495.1K
Q1 22	$483.6K
Q2 23	$231.6K
Q3 23	$198.5K
Q4 23	$394.6K
Q1 24	$166.7K
Q2 24	$250.7K
Q3 24	$328.4K
Q4 24	$174.4K
Q1 25	$570.2K
Q2 25	$122.2K
Q3 25	$39.5K
Q4 25	$176.9K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 21	-78.6%	+20.7%
Q2 21	-13.4%	+33.6%
Q3 21	+1146.3%	+5.9%
Q4 21	+14.9%	-18.7%
Q1 22	+21099.8%	+4.5%
Q2 23	-87.1%	-16.3%
Q3 23	-28.0%	-2.0%
Q4 23	-41.9%	+0.7%
Q1 24	-98.4%	-8.0%
Q2 24	+273.7%	+7.5%
Q3 24	-73.2%	-4.7%
Q4 24	-100.0%	-16.3%
Q1 25	-100.0%	-13.2%
Q2 25	-100.0%	-1.2%
Q3 25	-100.0%	-21.1%
Q4 25	—	-14.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 21	$1M	96.8%
Q2 21	$1M	33.1%
Q3 21	$1M	28.4%
Q4 21	$2M	69.4%
Q1 22	$2M	0.8%
Q2 23	$2M	316.4%
Q3 23	$1M	39.4%
Q4 23	$1M	111.0%
Q1 24	$1M	31.2%
Q2 24	$1M	72.8%
Q3 24	$1M	155.9%
Q4 24	$1M	—
Q1 25	$1M	—
Q2 25	$2M	—
Q3 25	$1M	—
Q4 25	$1M	—

OpEx Breakdown

Quarter	R&D	SG&A
Q1 21	$21M	$4M
Q2 21	$20M	$5M
Q3 21	$15M	$6M
Q4 21	$16M	$6M
Q1 22	$18M	$7M
Q2 23	$15M	$6M
Q3 23	$15M	$6M
Q4 23	$16M	$5M
Q1 24	$18M	$5M
Q2 24	$17M	$6M
Q3 24	$14M	$6M
Q4 24	$13M	$5M
Q1 25	$15M	$5M
Q2 25	$14M	$5M
Q3 25	$11M	$5M
Q4 25	$12M	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$181M	$196M	$377M
Q2 22	$146M	$217M	$363M
Q3 22	$89M	$251M	$340M
Q4 22	$112M	$205M	$317M
Q1 23	$94M	$202M	$296M
Q2 23	$80M	$197M	$278M
Q3 23	$87M	$176M	$263M
Q4 23	$86M	$152M	$238M
Q1 24	$87M	$135M	$222M
Q2 24	$84M	$119M	$203M
Q3 24	$84M	$99M	$183M
Q4 24	$81M	$109M	$190M
Q1 25	$104M	$63M	$167M
Q2 25	$104M	$41M	$146M
Q3 25	$105M	$28M	$133M
Q4 25	$105M	$13M	$118M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 21	29M	+16.6%	+34.7%
Q2 21	31M	+5.4%	+41.1%
Q3 21	32M	+5.1%	+17.9%
Q4 21	24M	-26.9%	-5.6%
Q1 22	33M	+40.4%	+13.7%
Q2 23	33M	-0.9%	+6.9%
Q3 23	33M	+0.0%	+1.7%
Q4 23	33M	+0.1%	+39.2%
Q1 24	33M	+0.0%	-0.8%
Q2 24	33M	+1.0%	+1.1%
Q3 24	33M	+0.0%	+1.1%
Q4 24	34M	+2.5%	+3.6%
Q1 25	37M	+8.4%	+12.2%
Q2 25	37M	+1.4%	+12.7%
Q3 25	37M	+0.0%	+12.7%
Q4 25	37M	+0.0%	+9.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 21	—	—
Q2 21	—	—
Q3 21	—	—
Q4 21	$13.9K	163
Q1 22	$1M	163
Q2 23	$3.0K	175
Q3 23	$18.5K	175
Q4 23	$8.0K	165
Q1 24	$21.1K	165
Q2 24	$12.0K	165
Q3 24	$5.3K	165
Q4 24	$0	155
Q1 25	$0	155
Q2 25	$0	155
Q3 25	$0	155
Q4 25	$0	130

Revenue / Employee